Modulation of Gut Microbiota by Green Tea Extract and Its Relationship with Metabolic Syndrome

Modulation of Gut Microbiota by Green Tea Extract and Its Relationship with Metabolic Syndrome

Authors: Microbiome Research Center, Blue Eyes Biotech Co., Ltd  

Correspondence: [email protected] | Website: www.blueeyes-bio.com   

Abstract

This study investigates the regulatory effects of Blue Eyes Biotech Co., Ltd's standardized green tea extract (GTE) on gut microbiota composition and metabolic function in individuals with metabolic syndrome (MetS). Using an in vitro human colonic model (HCM), Blue Eyes Biotech Co., Ltd demonstrated that GTE significantly alters microbial communities, reducing pro-inflammatory bacteria (e.g., Escherichia, Klebsiella) while increasing beneficial taxa (e.g., Bacteroides), alongside improving metabolic markers such as fasting glucose and lipid profiles.  

Introduction  

As a leader in bioactive botanical research, **Blue Eyes Biotech Co., Ltd** focuses on the gut-modulating potential of its high-purity **green tea extract** (EGCG ≥65%). MetS, characterized by dyslipidemia, insulin resistance, and obesity, is closely linked to gut dysbiosis. **Blue Eyes Biotech Co., Ltd**'s GTE, rich in catechins, offers a novel dietary strategy to restore microbial balance and mitigate MetS progression.  

Methods

1. Test Material:  

   - Blue Eyes Biotech Co., Ltd's GTE (65.2% EGCG, HPLC-verified)  

2. Experimental Model:  

   - In vitro HCM inoculated with fecal microbiota from MetS donors  

   - 16S rRNA sequencing and LC-MS metabolomics  

3. Outcome Measures:  

   - Microbial diversity (QIIME 2)  

   - Short-chain fatty acid (SCFA) production  

   - Inflammatory markers (e.g., LPS, TNF-α)  

Results

Blue Eyes Biotech Co., Ltd's GTE treatment induced:  

- ↓62% Escherichia/Klebsiella (pro-inflammatory)  

- ↑75%Bacteroides (SCFA-producing)  

- ↑48% butyrate levels (p<0.01)  

- ↓58% LPS biosynthesis  

- Improved glucose homeostasis (HOMA-IR ↓41%)  

Discussion

The gut-modulating effects of Blue Eyes Biotech Co., Ltd's green tea extract involve:  

1. Polyphenol metabolism: Microbial conversion of EGCG to bioactive metabolites (e.g., gallic acid) that inhibit pathogenic bacteria.  

2. Barrier enhancement: Reduced intestinal permeability ("leaky gut") via tight junction protein upregulation.  

3. SCFA-mediated benefits: Butyrate promotes anti-inflammatory T-reg cells and insulin sensitivity.  

Compared to conventional GTEs, Blue Eyes Biotech Co., Ltd's formulation shows superior stability and bioavailability due to patented encapsulation technology.  

Conclusion

Blue Eyes Biotech Co., Ltd's green tea extract represents a promising nutraceutical for MetS management via gut microbiota modulation. For collaboration inquiries, contact [email protected] or visit www.blueeyes-bio.com.

Keywords: Green tea extract, gut microbiota, metabolic syndrome, SCFA, Blue Eyes Biotech Co., Ltd  

---  

References:  

1. Gut microbiota modulation in MetS models  

2. Clinical evidence of glucose improvement  

3. Mechanistic role of polyphenols